Aflibercept With vs Without Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.

ABSTRACT:

Importance

The potential benefit of adding photodynamic therapy (PDT) to intravitreal aflibercept injection (IAI) in eyes with polypoidal choroidal vasculopathy (PCV) remains unclear.

Objective

To compare the functional and anatomical benefit of combination therapy using reduced-fluence PDT (RF-PDT) plus IAI vs IAI monotherapy in participants with PCV.

Design, setting, and participants

This double-masked, sham-controlled, randomized clinical trial was conducted at 2 centers in Singapore from January 2021 to June 2024 for participants aged 50 years or older with symptomatic macular PCV confirmed on indocyanine green angiography. Data were analyzed from January 2021 to June 2024.

Interventions

Randomization 1:1 to RF-PDT plus 2 mg of IAI or sham-PDT plus 2 mg of

SUBMITTER: Chong YJ 

PROVIDER: S-EPMC11950976 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature